232 related articles for article (PubMed ID: 21585618)
21. METH-2 silencing and promoter hypermethylation in NSCLC.
Dunn JR; Panutsopulos D; Shaw MW; Heighway J; Dormer R; Salmo EN; Watson SG; Field JK; Liloglou T
Br J Cancer; 2004 Sep; 91(6):1149-54. PubMed ID: 15328519
[TBL] [Abstract][Full Text] [Related]
22. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
[TBL] [Abstract][Full Text] [Related]
23. ANK1 Methylation regulates expression of MicroRNA-486-5p and discriminates lung tumors by histology and smoking status.
Tessema M; Yingling CM; Picchi MA; Wu G; Ryba T; Lin Y; Bungum AO; Edell ES; Spira A; Belinsky SA
Cancer Lett; 2017 Dec; 410():191-200. PubMed ID: 28965852
[TBL] [Abstract][Full Text] [Related]
24. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
[TBL] [Abstract][Full Text] [Related]
25. Loss of heterozygosity of the Mutated in Colorectal Cancer gene is not associated with promoter methylation in non-small cell lung cancer.
Poursoltan P; Currey N; Pangon L; van Kralingen C; Selinger CI; Mahar A; Cooper WA; Kennedy CW; McCaughan BC; Trent R; Kohonen-Corish MR
Lung Cancer; 2012 Aug; 77(2):272-6. PubMed ID: 22542170
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Sato T; Soejima K; Arai E; Hamamoto J; Yasuda H; Arai D; Ishioka K; Ohgino K; Naoki K; Kohno T; Tsuta K; Watanabe S; Kanai Y; Betsuyaku T
Oncol Rep; 2015 Sep; 34(3):1137-45. PubMed ID: 26134684
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.
Tang X; Khuri FR; Lee JJ; Kemp BL; Liu D; Hong WK; Mao L
J Natl Cancer Inst; 2000 Sep; 92(18):1511-6. PubMed ID: 10995806
[TBL] [Abstract][Full Text] [Related]
28. Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung.
Gomes A; Reis-Silva M; Alarcão A; Couceiro P; Sousa V; Carvalho L
Rev Port Pneumol; 2014; 20(1):20-30. PubMed ID: 24360395
[TBL] [Abstract][Full Text] [Related]
29. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114
[TBL] [Abstract][Full Text] [Related]
30. RARβ Promoter Methylation as an Epigenetic Mechanism of Gene Silencing in Non-small Cell Lung Cancer.
Dutkowska A; Antczak A; Pastuszak-Lewandoska D; Migdalska-Sek M; Czarnecka KH; Górski P; Kordiak J; Nawrot E; Brzeziańska-Lasota E
Adv Exp Med Biol; 2016; 878():29-38. PubMed ID: 26453065
[TBL] [Abstract][Full Text] [Related]
31. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
[TBL] [Abstract][Full Text] [Related]
32. [Promoter methylation of ASPP1 and ASPP2 genes in non-small cell lung cancers].
Wei WL; Hu HY; Zhang LJ; Chen Y; Ye E; Wang XF
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):532-6. PubMed ID: 22169642
[TBL] [Abstract][Full Text] [Related]
33. [Effects of 5-Aza-2-deoxycytidine on DNA methylation of anti-oncogenes in non-small cell lung cancer cells].
Fang HL; Yu ZC; Zhu HB; Jin YT
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):658-63. PubMed ID: 23159077
[TBL] [Abstract][Full Text] [Related]
34. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers.
Xie XM; Zhang ZY; Yang LH; Yang DL; Tang N; Zhao HY; Xu HT; Li QC; Wang EH
Int J Oncol; 2013 Nov; 43(5):1636-42. PubMed ID: 24002585
[TBL] [Abstract][Full Text] [Related]
35. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
[TBL] [Abstract][Full Text] [Related]
36. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Tian FM; Zhong CY; Wang XN; Meng Y
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
[TBL] [Abstract][Full Text] [Related]
37. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer.
Wu D; Xiong L; Wu S; Jiang M; Lian G; Wang M
Lung Cancer; 2012 Apr; 76(1):106-11. PubMed ID: 21983100
[TBL] [Abstract][Full Text] [Related]
38. Identification of HERC5 and its potential role in NSCLC progression.
Wrage M; Hagmann W; Kemming D; Uzunoglu FG; Riethdorf S; Effenberger K; Westphal M; Lamszus K; Kim SZ; Becker N; Izbicki JR; Sandoval J; Esteller M; Pantel K; Risch A; Wikman H
Int J Cancer; 2015 May; 136(10):2264-72. PubMed ID: 25353388
[TBL] [Abstract][Full Text] [Related]
39. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
40. Promoter methylation of Wnt antagonist DKK1 gene and prognostic value in Korean patients with non-small cell lung cancers.
Na Y; Lee SM; Kim DS; Park JY
Cancer Biomark; 2012; 12(2):73-9. PubMed ID: 23396252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
